CYP2A6: Genetics, structure, regulation, and function

Drug Metabolism and Drug Interactions

Volumn 27, Issue 2, 2012, Pages 73-88

  Raunio, Hannu ^a   Rahnasto Rilla, Minna ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cigarette smoking; CYP2A6; Genetic polymorphisms; Nicotine

Indexed keywords

ARTEMISININ; CARBAMAZEPINE; COTININE; COUMARIN; CYTOCHROME P450 2A6; DEXAMETHASONE; EFAVIRENZ; ESTROGEN RECEPTOR ALPHA; GENISTEIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HALOTHANE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; ISONIAZID; LETROZOLE; LOSIGAMONE; MENTHOL; METHOXSALEN; METHOXYFLURANE; MIFEPRISTONE; NICOTINE; ORGANOSULFUR DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; RIFAMPICIN; TEGAFUR; TRANYLCYPROMINE; TRYPTAMINE; UNINDEXED DRUG; VALPROIC ACID; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; COUMARIN DERIVATIVE; ENZYME INHIBITOR; NICOTINIC AGENT; UNSPECIFIC MONOOXYGENASE;

ALLELE; BONE MARROW SUPPRESSION; CANCER RISK; CONFERENCE PAPER; DIARRHEA; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVE SITE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE STRUCTURE; GENETIC POLYMORPHISM; GENOTYPE; GRAPEFRUIT JUICE; HOMOZYGOTE; HORMONE METABOLISM; HORMONE RESPONSIVE ELEMENT; HUMAN; LIVER CIRRHOSIS; LIVER METABOLISM; LIVER TOXICITY; LUNG CANCER; MULTIGENE FAMILY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; RISK ASSESSMENT; SMOKING; ANIMAL; BIOSYNTHESIS; CHEMICAL STRUCTURE; DRUG ANTAGONISM; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; NEOPLASM; REVIEW;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICE; MODELS, MOLECULAR; MULTIGENE FAMILY; NEOPLASMS; NICOTINE; NICOTINIC AGONISTS; POLYMORPHISM, GENETIC; SMOKING; SUBSTRATE SPECIFICITY;

EID: 84867320452     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0001     Document Type: Conference Paper

References (188)

1. Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 1995;5:S123-8.
2. Chang TK, Waxman DJ. CYP2A subfamily. In: Ioannides C, editor. Cytochrome P450-metabolic and toxicological aspects. Boca Raton, FL: CRC Press, 1996:99-134.
3. Honkakoski P, Negishi M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Rev 1997;29:977-96. (Pubitemid 28133454)
4. Su T, Ding X. Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharmacol 2004;199:285-94. (Pubitemid 39208728)
5. Raunio H, Hakkola J, Pelkonen O. The CYP2A subfamily. In: Ioannides C, editor. Cytochrome P450-role in metabolism and toxicity of drugs and other xenobiotics. Cambridge: RSC, Advancing the Chemical Sciences Publishing, 2008:151-71.
6. Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW. Organization and evolution of the cytochrome P450 CYP2A- 2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol 1995;41:894-900. (Pubitemid 26020067)
7. Hoffman SM, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001;11:687-98. (Pubitemid 33078238)
8. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identifi cation of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990;267:365-71. (Pubitemid 20136067)
9. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-9. (Pubitemid 20053858)
10. Yun CH, Shimada T, Guengerich FP. Purifi cation and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991;40:679-85.
11. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999;57:1407-13. (Pubitemid 29225104)
12. Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing AB, Eisenacher M, et al. Distinction between human cytochrome P450 (CYP) isoforms and identifi cation of new phosphorylation sites by mass spectrometry. J Proteome Res 2008;7:4678-88.
13. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high effi ciency metabolic activation of a tobacco-specifi c carcinogen, 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. Cancer Res 2000;60:5074-9.
14. Chen Y, Liu YQ, Su T, Ren X, Shi L, Liu D, et al. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. Biochem Pharmacol 2003;66:1245-51. (Pubitemid 37130299)
15. Newland N, Baxter A, Hewitt K, Minet E. CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In vitro 2011;25:922-9.
16. Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002;32:391-411. (Pubitemid 35191358)
17. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-73. (Pubitemid 37372638)
18. Hakkola J, Tanaka E, Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 1998;82:209-17. (Pubitemid 28270559)
19. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300:355-60. (Pubitemid 34106223)
20. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001;29: 91-5. (Pubitemid 32112920)
21. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009;10:754-80.
22. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009;76:215-28.
23. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000;144:139-47. (Pubitemid 30201630)
24. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006;79:480-8.
25. Sinues B, Fanlo A, Mayayo E, Carcas C, Vicente J, Arenaz I, et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. Hum Exp Toxicol 2008;27:367-72.
26. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 2010;66:239-51.
27. Dempsey D, Jacob P III, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002;301:594-8. (Pubitemid 34429972)
28. Zhang Y, Klein K, Sugathan A, Nassery N, Dombkowski A, Zanger UM, et al. Transcriptional profi ling of human liver identifi es sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One 2011;6:e23506.
29. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35:1935-41. (Pubitemid 47481589)
30. Bièche I, Girault I, Urbain E, Tozlu S, Lidereau R. Relationship between intratumoral expression of genes coding for xenobioticmetabolizing enzymes and benefi t from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 2004;6:R252-63.
31. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115. (Pubitemid 40283970)
32. Palmer CN, Coates PJ, Davies SE, Shephard EA, Phillips IR. Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology 1992;16:682-7.
33. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA. Overexpression of cytochrome P-450 isoforms involved in afl atoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996;24:458-67. (Pubitemid 26274855)
34. Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000;33:893-901.
35. Yongvanit P, Phanomsri E, Namwat N, Kampan J, Tassaneeyakul W, Loilome W, et al. Hepatic cytochrome P450 2A6 and 2E1 status in peri-tumor tissues of patients with Opisthorchis viverriniassociated cholangiocarcinoma. Parasitol Int 2012;61:162-6.
36. Satarug S, Lang MA, Yongvanit P, Sithithaworn P, Mairiang E, Mairiang P, et al. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, Opisthorchiasis viverrini. Cancer Epidemiol Biomarkers Prev 1996;5:795-800. (Pubitemid 26346278)
37. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Pääkkö P, Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998;27:427-32. (Pubitemid 28081057)
38. Renton KW. Regulation of drug metabolism and disposition during infl ammation and infection. Expert Opin Drug Metab Toxicol 2005;1:629-40.
39. Pasanen M, Rannala Z, Tooming A, Sotaniemi EA, Pelkonen O, Rautio A. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 1997;123:177-84. (Pubitemid 27443389)
40. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J, Lange R. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 1991;200:511-7.
41. Dalet-Beluche I, Boulenc X, Fabre G, Maurel P, Bonfils C. Purifi cation of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. Eur J Biochem 1992;204:641-8.
42. Mattes WB, Li AP. Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. Chem Biol Interact 1997;107:47-61. (Pubitemid 27509000)
43. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H, et al. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 2000;28:1321-6.
44. Meunier V, Bourrié M, Julian B, Marti E, Guillou F, Berger Y, et al. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 2000;30:589-607. (Pubitemid 30449569)
45. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-57. (Pubitemid 33104951)
46. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31:282-8. (Pubitemid 36249682)
47. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31. (Pubitemid 36378519)
48. Sotaniemi EA, Rautio A, Bäckstrom M, Arvela P, Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 1995;39:71-6.
49. Williams JM, Gandhi KK, Benowitz NL. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. Cancer Epidemiol Biomarkers Prev 2010;19:2582-9.
50. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, et al. Identifi cation of a novel human constitutive androstane receptor (CAR) agonist and its use in the identifi cation of CAR target genes. J Biol Chem 2003;278:17277-83. (Pubitemid 36799610)
51. Asimus S, Hai TN, Van Huong N, Ashton M. Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 2008;64:283-92.
52. Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alphamediated transcription. Drug Metab Pharmacokinet 2008;23: 2-7.
53. Jover R, Moya M, Gómez-Lechón MJ. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr Drug Metab 2009;10:508-19.
54. Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001;33:668-75. (Pubitemid 32185230)
55. Ulvila J, Arpiainen S, Pelkonen O, Aida K, Sueyoshi T, Negishi M, et al. Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I. Biochem J 2004;381:887-94. (Pubitemid 39120500)
56. Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids 2007;72:231-46. (Pubitemid 46273513)
57. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007;35:1700-10. (Pubitemid 47296067)
58. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, et al. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor- coactivator 1 . J Pharmacol Exp Ther 2006;319:693-702.
59. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, et al. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 to the proximal promoter. Mol Pharmacol 2008;73:451-60. (Pubitemid 351159215)
60. Denton TT, Zhang X, Cashman Jr. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 2004;67:751-6. (Pubitemid 38125259)
61. Hukkanen J, Jacob P, Peng M, Dempsey D, Benowitz NL. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010;69:152-9.
62. Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Downregulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 2003;63:96-104. (Pubitemid 36043813)
63. Kirby GM, Nichols KD, Antenos M. CYP2A5 induction and hepatocellular stress: an adaptive response to perturbations of heme homeostasis. Curr Drug Metab 2011;12:186-97.
64. Abu-Bakar A, Hakkola J, Juvonen R, Rahnasto-Rilla M, Raunio H, Lang MA. Function and regulation of the Cyp2a5 / CYP2A6 genes in response to toxic insults. Curr Drug Metab 2012; Mar 19, in press.
65. Yokota S, Higashi E, Fukami T, Yokoi T, Nakajima M. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol 2011;81:289-94.
66. Gilmore J, Rotondo F, Pelletier AM, LaMarre J, Alaoui-Jamali M, Kirby GM. Identifi cation of a 43-kDa protein in human liver cytosol that binds to the 3 -untranslated region of CYP2A6 mRNA. Biochem Pharmacol 2001;62:669-78. (Pubitemid 32816983)
67. Christian K, Lang M, Maurel P, Raffalli-Mathieu F. Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. Mol Pharmacol 2004;65: 1405-14. (Pubitemid 38668299)
68. Wang J, Pitarque M, Ingelman-Sundberg M. 3 -UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 2006;340:491-7. (Pubitemid 43021775)
69. Wood AW, Conney AH. Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus). Science 1974;185:612-4.
70. Honkakoski P, Mäenpää J, Leikola J, Pasanen M, Juvonen R, Lang MA, et al. Cytochrome P4502A-mediated coumarin 7- hydroxylation and testosterone hydroxylation in mouse and rat lung. Pharmacol Toxicol 1993;72:107-12. (Pubitemid 23085503)
71. Zhou X, Zhuo X, Xie F, Kluetzman K, Shu YZ, Humphreys WG, et al. Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther 2010;332:578-87.
72. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-9. (Pubitemid 20053858)
73. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P III, Benowitz NL. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N -oxide. Chem Res Toxicol 1992;5:639-46.
74. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996;24:1212-7. (Pubitemid 26423061)
75. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Pharmacol Exp Ther 1997;282:1608-14. (Pubitemid 27408347)
76. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyfl urane and sevofl urane metabolism. Intrarenal fl uoride production as a possible mechanism of methoxyfl urane nephrotoxicity. Anesthesiology 1995;82:689-99.
77. Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000;55:853-9. (Pubitemid 30201768)
78. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997;283:698-703. (Pubitemid 27514629)
79. Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The infl uence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010;112:320-3.
80. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61:197-216.
81. Endo T, Ban M, Hirata K, Yamamoto A, Hara Y, Momose Y. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab Dispos 2007;35:476-83. (Pubitemid 46333912)
82. Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009;39:795-802.
83. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011;90: 693-700.
84. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al.; Swiss HIV Cohort Study. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009;19:300-9.
85. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009;67: 427-36.
86. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, et al. Bioactivation of tegafur to 5-fl uorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000;6:4409-15.
87. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fl uorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 2000;28:1457-63.
88. Kajita J, Fuse E, Kuwabara T, Kobayashi H. The contribution of cytochrome P450 to the metabolism of tegafur in human liver. Drug Metab Pharmacokinet 2003;18:303-9.
89. Wang H, Bian T, Liu D, Jin T, Chen Y, Lin A, et al. Association analysis of CYP2A6 genotypes and haplotypes with 5-fl uorouracil formation from tegafur in human liver microsomes. Pharmacogenomics 2011;12:481-92.
90. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 2011;7:715-26.
91. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33. (Pubitemid 41553963)
92. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715.
93. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448. (Pubitemid 34311090)
94. Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, et al. CYP2A6 and the plasma level of 5-chloro-2, 4- dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fl uorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008;99:1049-54. (Pubitemid 351997611)
95. European Medicines Agency. Guideline on the investigation of drug interactions (Draft). EMA/CHMP/EWP/125211/2010.
96. Zhang L, Reynolds KS, Zhao P, Huang SM. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 2010;243:134-45.
97. Felter SP, Vassallo JD, Carlton BD, Daston GP. A safety assessment of coumarin taking into account species-specifi city of toxicokinetics. Food Chem Toxicol 2006;44:462-75. (Pubitemid 43375122)
98. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Characterization of CYP2A6 involved in 3 -hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996;277:1010-5.
99. Crespi CL, Penman BW, Leakey JA, Arlotto MP, Stark A, Parkinson A, et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 1990;11:1293-300. (Pubitemid 20245700)
100. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobaccorelated nitrosamines in human liver microsomes. Carcinogenesis 1992;13:1789-94.
101. Duescher RJ, Elfarra AA. Human liver microsomes are effi cient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch Biochem Biophys 1994;311:342-9. (Pubitemid 24220153)
102. Reigh G, McMahon H, Ishizaki M, Ohara T, Shimane K, Esumi Y, et al. Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis 1996;17:1989-96. (Pubitemid 26325394)
103. Ding X, Spink DC, Bhama JK, Sheng JJ, Vaz AD, Coon MJ. Metabolic activation of 2,6-dichlorobenzonitrile, an olfactoryspecifi c toxicant, by rat, rabbit, and human cytochromes P450. Mol Pharmacol 1996;49:1113-21. (Pubitemid 26181437)
104. Hong JY, Wang YY, Bondoc FY, Lee M, Yang CS, Hu WY, et al. Metabolism of methyl tert-butyl ether and other gasoline ethers by human liver microsomes and heterologously expressed human cytochromes P450: identifi cation of CYP2A6 as a major catalyst. Toxicol Appl Pharmacol 1999;160:43-8. (Pubitemid 29489762)
105. Shamsipur M, Miran Beigi AA, Teymouri M, Poursaberi T, Mostafavi SM, Soleimani P, et al. Biotransformation of methyl tert-butyl ether by human cytochrome P450 2A6. Biodegradation 2011;Mar 19:Epub ahead of print.
106. Gemma S, Vittozzi L, Testai E. Metabolism of chloroform in the human liver and identifi cation of the competent P450s. Drug Metab Dispos 2003;31:266-74. (Pubitemid 36249680)
107. Sweeney C, Coles BF, Nowell S, Lang NP, Kadlubar FF. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology 2002;27:183-7.
108. Nowell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:377-83. (Pubitemid 34408217)
109. Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, et al. CYP2A6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos 2005;33:1361-6. (Pubitemid 41196980)
110. Wu ZL, Podust LM, Guengerich FP. Expansion of substrate specifi city of cytochrome P450 2A6 by random and site-directed mutagenesis. J Biol Chem 2005;280:41090-100. (Pubitemid 41780604)
111. Miyazawa M, Gyoubu K. Roles of human CYP2A6 and rat CYP2B1 in the oxidation of (+) -fenchol by liver microsomes. Xenobiotica 2007;37:943-53. (Pubitemid 47482943)
112. Miyazawa M, Marumoto S, Takahashi T, Nakahashi H, Haigou R, Nakanishi K. Metabolism of (+) - and (-)-menthols by CYP2A6 in human liver microsomes. J Oleo Sci 2011;60:127-32.
113. Nakahashi H, Miyazawa M. Biotransformation of (-)-camphor by Salmonella typhimurium OY1002/2A6 expressing human CYP2A6 and NADPH-P450 reductase. J Oleo Sci 2011;60:545-8.
114. Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone, a tobacco specifi c carcinogen. Chem Res Toxicol 2005;18:95-110. (Pubitemid 40267791)
115. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008;21:160-71. (Pubitemid 351219717)
116. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-41. (Pubitemid 351417076)
117. Benowitz NL, Samet JM. The threat of menthol cigarettes to US public health. N Engl J Med 2011;364:2179-81.
118. Abu-Bakar A, Arthur DM, Aganovic S, Ng JC, Lang MA. Inducible bilirubin oxidase: a novel function for the mouse cytochrome P450 2A5. Toxicol Appl Pharmacol 2011;257:14-22.
119. Mäenpää J, Juvonen R, Raunio H, Rautio A, Pelkonen O. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 1994;48:1363-9. (Pubitemid 24318139)
120. Draper AJ, Madan A, Parkinson A. Inhibition of coumarin 7- hydroxylase activity in human liver microsomes. Arch Biochem Biophys 1997;341:47-61. (Pubitemid 27198030)
121. Koenigs LL, Trager WF. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 1998;37:10047-61. (Pubitemid 28366359)
122. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specifi c and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001;29:897-902. (Pubitemid 32488648)
123. Kimonen T, Juvonen RO, Alhava E, Pasanen M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol 1995;114:832-6.
124. Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 2001;29:217-22. (Pubitemid 32179519)
125. Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD. (R)- (+) -Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos 1998;26:701-4. (Pubitemid 28345854)
126. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K, et al. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis 2005;26:1947-55. (Pubitemid 41631269)
127. Fujita K, Kamataki T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab Dispos 2001;29:983-9. (Pubitemid 32605913)
128. Higashi E, Nakajima M, Katoh M, Tokudome S, Yokoi T. Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos 2007;35:508-14. (Pubitemid 46513276)
129. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002;57:799-804. (Pubitemid 34143338)
130. MacDougall JM, Fandrick K, Zhang X, Serafi n SV, Cashman Jr. Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. Chem Res Toxicol 2003;16:988-93. (Pubitemid 37047916)
131. Benowitz NL, Herrera B, Jacob P III. Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther 2004;310:1208-15. (Pubitemid 39108943)
132. Rahnasto M, Raunio H, Poso A, Juvonen RO. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde. Xenobiotica 2003;33:529-39. (Pubitemid 36688108)
133. Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem 2005;48:440-9. (Pubitemid 40139786)
134. Hukkanen J, Jacob P III, Benowitz NL. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther 2006;80:522-30. (Pubitemid 44767880)
135. Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, et al. Isofl avones inhibit nicotine C-oxidation catalyzed by human CYP2A6. J Clin Pharmacol 2006;46:337-44. (Pubitemid 43260321)
136. Denton TT, Zhang X, Cashman Jr. 5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem 2005;48:224-39. (Pubitemid 40105261)
137. Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman Jr. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem 2006;49:6987-7001. (Pubitemid 44885987)
138. Yoo HH, Lee MW, Kim YC, Yun CH, Kim DH. Mechanismbased inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas. Drug Metab Dispos 2007;35:1759-65.
139. Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 2008;324:992-9. (Pubitemid 351397848)
140. Rahnasto M, Wittekindt C, Juvonen RO, Turpeinen M, Petsalo A, Pelkonen O, et al. Identifi cation of inhibitors of the nicotine metabolising CYP2A6 enzyme-an in silico approach. Pharmacogenomics J 2008;8:328-38.
141. Chougnet A, Woggon WD, Locher E, Schilling B. Synthesis and in vitro activity of heterocyclic inhibitors of CYP2A6 and CYP2A13, two cytochrome P450 enzymes present in the respiratory tract. Chembiochem 2009;10:1562-7.
142. Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, et al. Mechanism-based inhibition of cytochrome P450 (CYP) 2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol 2011;163:1250-62.
143. Rahnasto MK, Raunio HA, Wittekindt C, Salminen KA, Leppänen J, Juvonen RO, et al. Identifi cation of novel CYP2A6 inhibitors by virtual screening. Bioorg Med Chem 2011; 19:7186-93.
144. Sellers EM, Tyndale RF. Mimicking gene defects to treat drug dependence. Ann NY Acad Sci 2000;909:233-46. (Pubitemid 30462042)
145. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) metabolism in vivo. Nicotine Tob Res 2003;5:891-9. (Pubitemid 38029085)
146. Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, et al. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004;32: 1402-10. (Pubitemid 39564560)
147. Aoki K, Kashiwagura Y, Horie T, Sato H, Tateno C, Ozawa N, et al. Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 2006;21:277-85.
148. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 1990;22:503-29.
149. Riveiro ME, De Kimpe N, Moglioni A, Vázquez R, Monczor F, Shayo C, et al. Coumarins: old compounds with novel promising therapeutic perspectives. Curr Med Chem 2010;17:1325-38.
150. Abraham K, Wöhrlin F, Lindtner O, Heinemeyer G, Lampen A. Toxicology and risk assessment of coumarin: focus on human data. Mol Nutr Food Res 2010;54:228-39.
151. Raunio H, Rautio A, Gullstén H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001;52:357-63. (Pubitemid 32939440)
152. Rietjens IM, Punt A, Schilter B, Scholz G, Delatour T, van Bladeren PJ. In silico methods for physiologically based biokinetic models describing bioactivation and detoxifi cation of coumarin and estragole: implications for risk assessment. Mol Nutr Food Res 2010;54:195-207.
153. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362: 2295-303.
154. Murphy SE, Raulinaitis V, Brown KM. Nicotine 5 -oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 2005;33:1166-73. (Pubitemid 41043760)
155. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007;8:1385-402. (Pubitemid 350162852)
156. Bloom J, Hinrichs AL, Wang JC, von Weymarn LB, Kharasch ED, Bierut LJ, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European- Americans. Pharmacogenet Genomics 2011;21:403-16.
157. Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 2010;5:17-29.
158. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 2007;119:e264-74. (Pubitemid 46397834)
159. O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 2004;13:422-8. (Pubitemid 39635932)
160. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010;42: 448-53.
161. Rodriguez S, Cook DG, Gaunt TR, Nightingale CM, Whincup PH, Day IN. Combined analysis of CHRNA5, CHRNA3 and CYP2A6 in relation to adolescent smoking behaviour. J Psychopharmacol 2011;25:915-23.
162. Verde Z, Santiago C, Rodríguez González-Moro JM, de Lucas Ramos P, López Martín S, Bandrés F, et al.'Smoking genes': a genetic association study. PLoS One 2011;6:e26668.
163. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011;106:985-94.
164. Siedlinski M, Cho MH, Bakke P, Gulsvik A, Lomas DA, Anderson W, et al; the COPDGene Investigators and ECLIPSE Investigators. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011;66: 894-902.
165. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, et al., on behalf of the ICGN, ECLIPSE, and COPDGene Investigators. A genome-wide association study of COPD identifi es a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012;21:947-57.
166. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5.
167. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001;29:548-52. (Pubitemid 32275533)
168. Khokhar JY, Ferguson CS, Zhu AZ, Tyndale RF. Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. Annu Rev Pharmacol Toxicol 2010;50:39-61.
169. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000;68:35-43. (Pubitemid 30609825)
170. Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 2007;47:541-64.
171. Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, et al. Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. Xenobiotica 2008;38:34-47.
172. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman- Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010;127:1-17.
173. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3- CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011;103:1342-6.
174. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354: 333-42. (Pubitemid 43145058)
175. Rossini A, de Almeida Simão T, Albano RM, Pinto LF. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008;9:1737-52.
176. Hollander MC, Zhou X, Maier CR, Patterson AD, Ding X, Dennis PA. A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis 2011;32:1279-84.
177. Otyepka M, Skopalík J, Anzenbacherová E, Anzenbacher P. What common structural features and variations of mammalian P450s are known to date? Biochim Biophys Acta 2007;1770:376-89. (Pubitemid 46136748)
178. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 2005;12:822-3. (Pubitemid 43086258)
179. He XY, Shen J, Hu WY, Ding X, Lu AY, Hong JY. Identifi cation of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys 2004;427:143-53. (Pubitemid 38757763)
180. Kim D, Wu ZL, Guengerich FP. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J Biol Chem 2005;280:40319-27. (Pubitemid 41779169)
181. Sansen S, Hsu MH, Stout CD, Johnson EF. Structural insight into the altered substrate specifi city of human cytochrome P450 2A6 mutants. Arch Biochem Biophys 2007;464:197-206. (Pubitemid 47210930)
182. DeVore NM, Smith BD, Wang JL, Lushington GH, Scott EE. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab Dispos 2009;37:1319-27.
183. Devore NM, Meneely KM, Bart AG, Stephens ES, Battaile KP, Scott EE. Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J 2011;doi: 10.1111/j.1742-4658.2011.08412.x.
184. Lindberg RL, Negishi M. Alteration of mouse cytochrome P450coh substrate specifi city by mutation of a single aminoacid residue. Nature 1989;339:632-4.
185. Negishi M, Uno T, Darden TA, Sueyoshi T, Pedersen LG. Structural fl exibility and functional versatility of mammalian P450 enzymes. FASEB J 1996;10:683-9. (Pubitemid 26172814)
186. Poso A, Gynther J, Juvonen R. A comparative molecular fi eld analysis of cytochrome P450 2A5 and 2A6 inhibitors. J Comput Aided Mol Des 2001;15:195-202. (Pubitemid 32219934)
187. Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. Predictive value of comparative molecular fi eld analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol In vitro 2003;17: 449-55. (Pubitemid 36776786)
188. Lewis DF, Ito Y, Goldfarb PS. Structural modelling of the human drug-metabolizing cytochromes P450. Curr Med Chem 2006;13:2645-52. (Pubitemid 44364142)